Cogent Biosciences, Inc. Increase (Decrease) in Contract with Customer, Liability
Cogent Biosciences, Inc. (COGT) reported Increase (Decrease) in Contract with Customer, Liability of -$1.31 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2022-03-15
- Cogent Biosciences, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2020-12-31 was $0.00.
- Cogent Biosciences, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2020-09-30 was -$312.00K.
- Cogent Biosciences, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2020-06-30 was -$529.00K.
- Cogent Biosciences, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2020-03-31 was -$474.00K.
- Cogent Biosciences, Inc. increase (decrease) in contract with customer, liability for fiscal 2020 was -$1.31M.
- Cogent Biosciences, Inc. increase (decrease) in contract with customer, liability for fiscal 2019 was -$16.63M.
- Cogent Biosciences, Inc. increase (decrease) in contract with customer, liability for fiscal 2018 was -$3.84M.
- Cogent Biosciences, Inc. increase (decrease) in contract with customer, liability for fiscal 2017 was -$3.88M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$312.00K derived: sum of 2 quarters · filed 2022-03-15 | -$841.00K derived: sum of 3 quarters · filed 2022-03-15 | -$1.31M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$312.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$841.00K derived: sum of 2 quarters · filed 2021-11-10 | -$1.31M 10-Q · filed 2021-11-10 | -$14.72M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$529.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$1.00M 10-Q · filed 2021-08-16 | -$14.40M derived: sum of 3 quarters · filed 2021-08-16 | -$14.86M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | -$474.00K 10-Q · filed 2021-05-12 | -$13.88M derived: sum of 2 quarters · filed 2021-05-12 | -$14.33M derived: sum of 3 quarters · filed 2021-05-12 | -$16.09M derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | -$13.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$13.86M derived: sum of 2 quarters · filed 2021-03-16 | -$15.62M derived: sum of 3 quarters · filed 2021-03-16 | -$16.63M 10-K · filed 2021-03-16 |
| 2019-09-30 | -$458.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$2.22M derived: sum of 2 quarters · filed 2020-11-09 | -$3.23M 10-Q · filed 2020-11-09 | -$5.37M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | -$1.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | -$2.77M 10-Q · filed 2020-08-11 | -$4.91M derived: sum of 3 quarters · filed 2020-08-11 | -$5.53M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | -$1.01M 10-Q · filed 2020-05-11 | -$3.15M derived: sum of 2 quarters · filed 2020-05-11 | -$3.77M derived: sum of 3 quarters · filed 2020-05-11 | -$4.24M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | -$2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | -$2.76M derived: sum of 2 quarters · filed 2020-03-26 | -$3.23M derived: sum of 3 quarters · filed 2020-03-26 | -$3.84M 10-K · filed 2020-03-26 |
| 2018-09-30 | -$623.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$1.09M derived: sum of 2 quarters · filed 2019-11-12 | -$1.71M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$465.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | -$1.08M 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | -$619.00K 10-Q · filed 2019-05-13 | |||
| 2017-12-31 | -$3.88M 10-K · filed 2019-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |